Pfizer and its German partner BioNTech will supply 100 million more doses of their coronavirus vaccine to the United States by this summer after protracted negotiations over how much the companies could deliver, given their commitments to other nations.
The $1.95 billion agreement doubles the overall U.S. order for the vaccine to 200 million doses. Pfizer and BioNTech said they can supply 70 million doses by June 30, 2021, with the remaining 30 million doses delivered by the end of July.
The expanded agreement comes one week after Health and Human Services Secretary Alex Azar told reporters that Pfizer was dealing with “manufacturing challenges,” a charge the company vehemently denied. “Pfizer has not had any production issues with its COVID-19 vaccine, and no shipments containing the vaccine are on hold or delayed,” a spokesperson said.